Syndax Pharmaceuticals, Inc. (SNDX)

21,86 -0,11 (-0,50%) Alla chiusura: 04:00PM EDT

Syndax Pharmaceuticals, Inc.

35 Gatehouse Drive
Building D Floor 3
Waltham, MA 02451
United States
781 419 1400
https://www.syndax.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 184

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Michael A. Metzger M.B.A.	CEO & Director	1,1M	126,68k	1971
Dr. Neil Gallagher M.D., Ph.D.	President, Head of Research & Development	720,46k	N/D	1964
Mr. Keith Alan Goldan CPA	CFO, Treasurer & Chief Accounting Officer	674,65k	N/D	1971
Mr. Luke J. Albrecht	Senior VP, General Counsel & Secretary	631,36k	387,36k	1979
Dr. Catherine Madigan M.D.	Chief Medical Officer	655,84k	N/D	1972
Dr. Peter Ordentlich B.Sc., Ph.D.	Co-Founder & Chief Scientific Officer	N/D	N/D	1969
Dr. Richard A. Heyman Ph.D.	Co-Founder	N/D	N/D	1957
Dr. Ronald M. Evans Ph.D.	Co-Founder, Advisor and Chair of Scientific Advisory Board	N/D	N/D	1949
Dr. Michael Downes Ph.D.	Co-Founder	N/D	N/D	N/D
Sharon Klahre	Vice President of Investor Relations & Communications	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Syndax Pharmaceuticals, Inc. al 1 maggio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.